Yesterday, Coherus filed its Petitioner Reply in IPR2016-00188 (U.S. Patent 9.017,680), IPR2016-00189 (9,073,987), and IPR2016-00172 (U.S. Patent 8,889,135). Each of these patents is owned by Abbvie, and, according to the documents filed in these IPRs, each relates to Humira® (adalimumab).
We have added these Replies to our IPR Tracker Page, where we post selected important filings in IPRs related to biologics.
The post Coherus Files Petitioner’s Reply in Three IPRs Relating to Abbvie’s Humira (adalimumab) appeared first on Big Molecule Watch.